Quick Summary

Cannabis sativa, commonly known as the hemp seed plant, contains bioactive compounds such as cannabinoids (e.g., cannabidiol (CBD), tetrahydrocannabinol (THC)), terpenes, and flavonoids. These compounds have diverse potential therapeutic applications currently under scientific investigation. Clinical research has explored effects on chronic pain, neurological disorders, cancer-related symptoms, dermatologic conditions, epilepsy, insomnia, and gastrointestinal disorders. Evidence levels vary; some randomized controlled trials (RCTs) support use of CBD in epilepsy and chronic pain, but many other indications require further high-quality clinical trials to confirm efficacy and safety. Safety concerns include potential liver toxicity, drug interactions, and adverse psychiatric effects. Regulatory and methodological challenges warrant cautious interpretation of existing data.

What is it

Hemp seed refers to the seeds of Cannabis sativa, a plant known for its bioactive cannabinoids including CBD and THC. These compounds interact with the body’s endocannabinoid system. Hemp seeds themselves are also a nutritional food source, while extracts from the plant are used for their potential health effects. Various formulations exist, including oils, tinctures, and topical preparations.

Traditional Uses

Traditionally, cannabis plants, including hemp, have been used for centuries in various cultures for their potential to relieve pain, reduce inflammation, promote sleep, and support neurological health. Traditional uses also include management of gastrointestinal discomfort and skin conditions. Modern therapeutic interest largely stems from these historical practices combined with emerging clinical evidence.

Active Compounds

  • Cannabinoids: cannabidiol (CBD), tetrahydrocannabinol (THC), and others
  • Terpenes: aromatic compounds contributing to the scent and purported effects
  • Flavonoids: plant metabolites with antioxidant properties

Potential Benefits with Evidence Levels

  • Chronic insomnia: A randomized controlled trial indicated Cannabis sativa oil improved sleep quality comparably to lorazepam over four weeks, with mild adverse events reported (PMID 41623556).
  • Drug-resistant epilepsy: Highly purified cannabidiol demonstrated moderate efficacy in reducing seizures among adults with drug-resistant epilepsy, supported by systematic review and meta-analysis of RCTs (PMID 39882324).
  • Neuropathic and chronic pain: Systematic and narrative reviews suggest cannabinoids have moderate efficacy in managing neuropathic pain, fibromyalgia, and cancer-related pain, though evidence is limited by small sample sizes and heterogeneity (PMID 40149508, 40872493).
  • Cancer-related symptoms (pain, anxiety): Cannabinoids may reduce cancer-associated pain and anxiety; however, evidence varies in quality and includes risks of psychiatric and other adverse effects (PMID 40748522, 39199679).
  • Dermatologic conditions (pruritus): Systematic reviews show cannabinoids may modestly reduce itching, but other skin outcomes have shown no significant benefits (PMID 41181596, 41008526).
  • Autism Spectrum Disorder (ASD): Cannabidiol-rich cannabis may improve some behavioral symptoms with mild adverse events, but further controlled trials are needed (PMID 39596518).
  • Opioid-induced constipation in cancer patients: Traditional herbal medicines, including cannabis derivatives, may improve symptoms with mainly mild gastrointestinal adverse effects; more high-quality trials are needed (PMID 41625337).
  • Bone health: Preclinical studies suggest CBD may promote bone formation and reduce resorption, though clinical confirmation is lacking (PMID 41595744).
  • Cancer therapy adjunct: Preclinical and early clinical evidence indicate potential anti-cancer effects of CBD and cannabinoids in breast cancer, gliomas, and lung cancer; limited clinical data currently available (PMID 40275168, 40781861, 41126219).

Side Effects

  • Hepatotoxic effects including elevated liver enzymes
  • Neuropsychiatric symptoms including anxiety, aggression, and psychiatric complications
  • Gastrointestinal symptoms such as diarrhea, nausea, and abdominal pain
  • Potential respiratory complications with inhalational use
  • Increased sedation and impairments when combined with other central nervous system depressants
  • Drug interaction-related toxicity
  • Local injection site reactions (reported in veterinary use)

Drug Interactions

  • Interactions mediated via cytochrome P450 enzymes (e.g., CYP2C19 inhibition leading to elevated clobazam metabolites)
  • Increased toxicity risk when combined with valproate (hepatotoxicity)
  • Possible interaction with opioids affecting safety and efficacy
  • Potential interactions affecting metabolism of antiseizure medications and other drugs

Who Should Avoid It

  • Individuals younger than 25 years due to unknown safety profile
  • Pregnant and breastfeeding women, as safety has not been established and potential risks exist
  • People on medications metabolized by CYP enzymes or with known cannabinoid hypersensitivity
  • Those with known hypersensitivity to cannabinoids or hemp products

Evidence Limitations

Many studies have limitations including small sample sizes, short duration, lack of standardized preparations and doses, and heterogeneous methodologies. Several indications rely heavily on preclinical or animal studies. Clinical evidence is strongest for CBD in specific epilepsy syndromes. More large, well-designed randomized controlled trials are required to confirm efficacy and safety across other uses. Safety data in younger populations, pregnant or lactating individuals, and those on concomitant medications remain insufficient.

References

Last Reviewed

June 2024

Disclaimer: This page is for informational purposes only and does not constitute medical advice. Consult a healthcare professional before starting any herbal or cannabinoid-based supplement, especially if you have underlying health conditions or take other medications.